important collaboration & supply agreement with MSD (June ’24) • Registrational Phase III trial in 1L NSCLC with ~750 patients • Immutep to conduct trial & retains commercial rights to efti • Potential to establish new standard of care in NSCLC, one of largest oncology indications and revenue drivers for KEYTRUDA • Planned KEYTRUDA supply has significant value (typical ICI drug supply for such a PIII trial is approx. US$100m) TACTI-003 Phase IIb Trial
important collaboration & supply agreement with MSD (June ’24) •...
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
-0.005(1.64%) |
Mkt cap ! $436.3M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 31.3¢ | 30.0¢ | $960.6K | 3.161M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 188729 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 46153 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |